ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $34,955 | -8.8% | 970,151 | 0.0% | 1.76% | +3.2% |
| Q4 2022 | $38,340 | -99.9% | 970,151 | 0.0% | 1.70% | -7.8% |
| Q3 2022 | $38,981,000 | -4.4% | 970,151 | 0.0% | 1.85% | +5.1% |
| Q2 2022 | $40,785,000 | +7.9% | 970,151 | 0.0% | 1.76% | +8.5% |
| Q1 2022 | $37,797,000 | -2.2% | 970,151 | 0.0% | 1.62% | -5.3% |
| Q4 2021 | $38,661,000 | +10.3% | 970,151 | 0.0% | 1.71% | +3.7% |
| Q3 2021 | $35,061,000 | -11.8% | 970,151 | 0.0% | 1.65% | -9.7% |
| Q2 2021 | $39,766,000 | -99.1% | 970,151 | 0.0% | 1.83% | -91.5% |
| Q1 2021 | $4,231,798,000 | +113.6% | 970,151 | -75.5% | 21.59% | -0.4% |
| Q4 2020 | $1,981,228,000 | +18.5% | 3,958,498 | -0.4% | 21.69% | +8.2% |
| Q3 2020 | $1,671,777,000 | -13.3% | 3,973,800 | 0.0% | 20.05% | -28.5% |
| Q2 2020 | $1,929,279,000 | – | 3,973,800 | – | 28.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |